PDE5A and melanoma: Interestingly, analysis on Basal Cell Carcinoma also shows that the risk of malignant melanoma is increased by 14% of the user of PDE5 inhibitor, though there is no clear biological mechanism for a possible association between PDE5 inhibitor use and basal cell carcinoma.